Last updated: September 7, 2026
Glucarpidase is a specialized rescue biologic used to rapidly reduce toxic methotrexate concentrations in patients with delayed clearance or methotrexate overdose. Its commercial market is small, hospital-based and highly concentrated, but the product has strong clinical differentiation because it can lower plasma methotrexate by about 97% within 15 minutes.[1]
The product, marketed as Voraxaze, has limited direct competition, no established biosimilar market and a use case tied to rare but medically urgent events. Its financial profile is therefore driven by high per-treatment value, hospital stocking and emergency availability rather than prescription volume. Public disclosures do not provide a standalone Voraxaze revenue line. The product changed ownership when SERB Pharmaceuticals acquired BTG’s specialty pharmaceutical business, including Voraxaze, after Boston Scientific acquired BTG in 2019.[2][3]
What is glucarpidase and how is Voraxaze used?
Glucarpidase is a recombinant bacterial carboxypeptidase G2 enzyme. It hydrolyzes methotrexate into inactive metabolites that are cleared independently of renal function. The FDA approved Voraxaze in January 2012 for patients with toxic plasma methotrexate concentrations greater than 1 micromole per liter and delayed methotrexate clearance or risk of methotrexate toxicity.[1]
Key product characteristics
| Attribute |
Glucarpidase / Voraxaze |
| Active ingredient |
Glucarpidase |
| Product type |
Recombinant enzyme biologic |
| FDA approval |
January 2012 |
| Initial sponsor |
BTG International Inc. |
| Current commercial owner |
SERB Pharmaceuticals |
| Primary use |
Toxic methotrexate exposure with delayed clearance |
| Administration |
Intravenous infusion |
| Label dose |
50 units/kg as a single dose |
| Treatment setting |
Hospital, oncology center, emergency or critical-care setting |
| FDA regulatory pathway |
Biologics license application |
| Main commercial risk |
Low event frequency and hospital inventory economics |
| Main competitive advantage |
Rapid enzymatic methotrexate removal |
The FDA label recommends administering glucarpidase over five minutes. It also warns that leucovorin, an essential component of methotrexate rescue, must be administered at a different time because glucarpidase can cleave leucovorin.[1]
How large is the glucarpidase market?
The addressable market is narrow because glucarpidase is not used for routine methotrexate therapy. It is reserved for serious toxicity, usually after high-dose methotrexate treatment when renal dysfunction causes delayed clearance.
Market demand is determined by:
- The number of institutions using high-dose methotrexate.
- The frequency of delayed methotrexate elimination.
- The number of patients who cross the treatment threshold.
- Hospital willingness to stock a high-cost emergency biologic.
- Regional oncology infrastructure and treatment protocols.
The product has an unusual demand curve. Utilization can remain low for long periods, then rise sharply during a cluster of toxicity cases or at a high-volume cancer center. Hospitals need immediate access because delaying treatment can increase renal, hepatic, neurologic and hematologic toxicity.
Estimated commercial structure
Public sources do not disclose a reliable global glucarpidase market size or a standalone Voraxaze revenue figure. The commercial structure is more important than a point estimate:
| Market characteristic |
Effect on financial performance |
| Rare-use rescue indication |
Limits annual unit volume |
| High clinical urgency |
Supports premium pricing |
| Few substitutes |
Reduces direct price competition |
| Hospital procurement |
Concentrates sales among institutional accounts |
| Short treatment course |
Limits repeat-patient revenue |
| Inventory requirements |
Creates demand independent of immediate case volume |
| Private ownership |
Reduces revenue transparency |
| Orphan-style economics |
Supports specialized sales and distribution |
Historical U.S. reports placed the price of a single vial near $10,000, although current transaction prices vary by contract, distributor and institution. A typical adult dose may require multiple 1,000-unit vials, making the acquisition cost of a treatment materially higher than the list price of one vial.[4] The pricing model can support attractive gross margins if manufacturing yields and inventory management are controlled.
What is the financial trajectory of Voraxaze?
Voraxaze has a structurally defensive but low-scale financial profile. Revenue is likely to be relatively resilient during periods of stable oncology demand because the product addresses a high-acuity event with few alternatives. Growth is constrained by the size of the toxicity population rather than by broad adoption.
Revenue drivers
The main revenue drivers are:
- Growth in high-dose methotrexate use.
- Expansion of pediatric and adult oncology centers.
- Improved awareness of delayed methotrexate clearance.
- Hospital protocols that require rapid access to glucarpidase.
- Wider stocking by specialty pharmacies and cancer hospitals.
- Price increases or contract repricing.
- Geographic expansion outside the United States.
Revenue constraints
The main constraints are:
- Low incidence of eligible toxicity events.
- High hospital budget impact.
- Expiration and wastage of stocked inventory.
- Limited evidence for use outside the approved indication.
- Clinical reliance on renal support and leucovorin rescue in some cases.
- Potential future competition from alternative methotrexate-clearing technologies.
A likely financial trajectory is a mature specialty-product profile rather than a high-growth biologic launch. Unit growth should remain modest. Revenue can still increase through price, institutional penetration and geographic expansion, but the ceiling is limited by the number of methotrexate toxicity cases.
SERB is privately held, and publicly available company materials do not provide a separate Voraxaze revenue series. Boston Scientific reported the divestiture of BTG’s specialty pharmaceutical business as part of its post-acquisition portfolio strategy, while SERB positioned the acquisition as an expansion of its rare-disease and specialty pharmaceutical platform.[2][3]
Who owns glucarpidase and how has ownership changed?
Ownership timeline
| Date |
Event |
| Before 2019 |
Voraxaze commercialized by BTG International |
| 2019 |
Boston Scientific completed its acquisition of BTG |
| 2020 |
SERB agreed to acquire BTG’s specialty pharmaceutical business |
| 2020-2021 |
SERB assumed commercial responsibility for the acquired specialty portfolio, including Voraxaze |
| Current commercial structure |
Voraxaze is associated with SERB Pharmaceuticals and its specialty pharmaceutical operations |
Boston Scientific’s acquisition of BTG was focused on interventional medicine and did not align with continued ownership of BTG’s pharmaceutical portfolio. SERB’s acquisition gave it established products with specialized hospital and rare-disease markets rather than early-stage development assets.[2][3]
The ownership change did not materially alter the product’s clinical role. It did change the strategic context. Under SERB, Voraxaze is part of a focused specialty portfolio where products with low volume and high medical value can be commercially relevant without requiring mass-market scale.
What is the FDA regulatory status of glucarpidase?
Voraxaze is FDA-approved under a biologics license application for the treatment of toxic methotrexate concentrations associated with delayed clearance or overdose.[1]
Regulatory milestones
| Milestone |
Date or status |
| FDA approval |
January 2012 |
| Dosage form |
Sterile lyophilized powder for injection |
| Approved route |
Intravenous |
| Pediatric use |
Included in the approved indication |
| Orphan-drug context |
Consistent with a rare, specialized oncology rescue indication |
| Current regulatory category |
Approved biologic |
| Generic substitution |
No conventional small-molecule generic substitution |
The product’s regulatory value comes from its narrow but clinically urgent indication. Approval did not establish glucarpidase as a general methotrexate antidote for all exposures. Its labeled population is tied to toxic plasma concentrations and delayed clearance or overdose.
What patents protect glucarpidase and Voraxaze?
The commercial protection for glucarpidase has historically depended on a combination of biologic manufacturing know-how, product-specific regulatory exclusivity, formulation protection and patent rights related to recombinant enzyme production and use.
Publicly accessible FDA Orange Book records are not a complete source for biologic patent information. The Orange Book primarily lists patents and exclusivities for approved drug products, while biologics are principally tracked through the Purple Book and related FDA records. A conventional Orange Book-style patent listing should not be treated as a complete measure of Voraxaze’s freedom from competition.[5][6]
Protection categories
| Protection category |
Relevance to glucarpidase |
| Product composition |
May cover recombinant glucarpidase or defined enzyme variants |
| Manufacturing process |
Can protect expression, purification and activity-control methods |
| Formulation |
May cover stability, lyophilization and reconstitution |
| Method of use |
May cover treatment of toxic methotrexate concentrations |
| Regulatory exclusivity |
Applies separately from patent term |
| Trade secrets |
Important for yield, impurity control and activity preservation |
For a protein rescue product with low annual volume, manufacturing know-how may be commercially more important than a single broad composition patent. A competitor must reproduce biological activity, purity, stability and batch consistency while satisfying FDA comparability requirements.
No widely reported public Paragraph IV challenge or major patent litigation has established an imminent U.S. generic launch for Voraxaze. The absence of a public challenge does not eliminate future competition, but it indicates that the product has not generated the type of patent dispute associated with major chronic-use medicines.
When does glucarpidase lose exclusivity?
FDA approval in 2012 initiated the product’s market life, but patent expiry and regulatory exclusivity are separate issues. Orphan-drug exclusivity generally lasts seven years from approval and blocks approval of the same drug for the same indication, subject to statutory exceptions. That period would not ordinarily remain the principal barrier more than a decade after approval.
The more relevant current barriers are:
- Manufacturing complexity.
- Limited commercial return for a competing product.
- Clinical and regulatory requirements for a biologic.
- Hospital procurement relationships.
- Need for emergency availability and reliable distribution.
- Potential formulation and process patents.
- Difficulty achieving sufficient market share to recover development costs.
A biosimilar or interchangeable designation would require a development program under the Public Health Service Act, including analytical characterization and potentially clinical evidence depending on FDA requirements. Because glucarpidase is an enzyme with a narrow rescue indication, the regulatory pathway may be feasible, but the commercial incentive is less obvious than for a high-volume monoclonal antibody.[7]
What generic or biosimilar entry risks exist?
Biosimilar risk
Glucarpidase is a biologic, so a true competitive product would generally proceed through the biosimilar pathway rather than the Hatch-Waxman generic pathway. A competitor would need to demonstrate high similarity to the reference product and address differences in protein structure, enzymatic activity, impurities, aggregation and stability.[7]
Biosimilar risk is currently limited by market economics. A rival would face:
- Low and irregular demand.
- Costly analytical and clinical development.
- Small hospital customer base.
- Need to maintain emergency supply.
- Potentially limited savings if the reference product is already tightly contracted.
- Manufacturing risk for a recombinant enzyme.
Generic entry risk
A conventional ANDA is unlikely to be the principal route because glucarpidase is a protein biologic. A non-biologic methotrexate rescue product would not be substitutable for glucarpidase because it would not perform the same enzymatic clearance function.
What formulations and manufacturing barriers protect Voraxaze?
Voraxaze is supplied as a lyophilized injectable product that requires reconstitution before intravenous use. The formulation must preserve enzymatic activity during storage and permit reliable preparation in an urgent hospital setting.
Key manufacturing barriers
The most significant technical barriers include:
- Recombinant protein expression.
- Consistent enzymatic activity.
- Control of host-cell proteins and other impurities.
- Prevention of aggregation and degradation.
- Sterile fill-finish production.
- Long-term stability of the lyophilized cake.
- Validated reconstitution performance.
- Batch-to-batch potency control.
These factors can create practical exclusivity even where patent protection is limited. A competing manufacturer must deliver a product that hospitals can store, reconstitute and administer rapidly without compromising safety or activity.
Which companies are challenging glucarpidase?
No major U.S. competitor has publicly established a commercial glucarpidase franchise comparable to Voraxaze. Competition is indirect and includes:
- Standard leucovorin rescue.
- Intensive hydration and urine alkalinization.
- Hemodialysis or continuous renal replacement therapy.
- Supportive management of methotrexate toxicity.
- Potential future recombinant enzymes or other methotrexate-degrading agents.
These approaches do not provide the same rapid enzymatic reduction in plasma methotrexate. As a result, they constrain use in some cases but do not represent direct product substitutes.
What patent litigation and settlement agreements affect glucarpidase?
Publicly reported litigation has not identified a major active Paragraph IV case, biosimilar dispute or settlement agreement involving Voraxaze that would set a near-term generic launch date. The product’s low volume and specialized manufacturing requirements reduce the incentive for patent litigation compared with high-revenue chronic therapies.
The absence of a disclosed settlement means there is no established public launch framework comparable to a negotiated generic-entry date. Commercial risk is more likely to arise from a new biologic entrant, a manufacturing disruption or hospital formulary pressure than from a conventional patent settlement.
How does glucarpidase compare with other specialty rescue drugs?
| Factor |
Glucarpidase |
Conventional oncology rescue or antidote |
| Primary role |
Rapid methotrexate removal |
Prevention or treatment of toxicity through supportive mechanisms |
| Patient population |
Narrow |
Often broader, depending on drug |
| Use frequency |
Low and episodic |
Variable |
| Pricing power |
High when clinically urgent |
Depends on competition |
| Administration |
Hospital IV |
Hospital or outpatient, depending on product |
| Manufacturing |
Recombinant enzyme |
Often small molecule or standard biologic |
| Competitive risk |
Low direct competition |
Often higher generic or therapeutic competition |
| Revenue profile |
High value per case, low volume |
Greater volume potential in broad indications |
Glucarpidase is more comparable to an emergency antidote than to a conventional oncology drug. Its commercial value is tied to preventing catastrophic toxicity and avoiding prolonged renal replacement therapy, intensive care and treatment interruption.
What is the investment outlook for glucarpidase?
The product has a stable niche profile but limited standalone growth potential. The strongest investment characteristics are:
- High clinical differentiation.
- Few direct substitutes.
- Hospital demand linked to urgent need.
- Specialized manufacturing barriers.
- Portfolio fit within a rare-disease pharmaceutical company.
The main weaknesses are:
- Limited patient volume.
- Lack of disclosed standalone revenue.
- Dependence on institutional purchasing.
- Inventory wastage risk.
- Potential pressure from hospital cost controls.
- Uncertain return on investment for lifecycle expansion.
- Limited ability to expand beyond the methotrexate toxicity market.
For SERB, Voraxaze is likely more valuable as part of a diversified specialty portfolio than as a standalone growth asset. Portfolio economics can benefit from shared sales infrastructure, specialty distribution and hospital relationships across rare-disease and emergency products.
Key Takeaways
- Glucarpidase, marketed as Voraxaze, is an FDA-approved recombinant enzyme for toxic methotrexate concentrations with delayed clearance or overdose.
- The product’s commercial market is small, hospital-based and concentrated among oncology centers.
- Its financial model depends on premium pricing, emergency availability and institutional stocking rather than high prescription volume.
- SERB Pharmaceuticals acquired the specialty pharmaceutical business that included Voraxaze after Boston Scientific acquired BTG.
- Public disclosures do not provide a standalone Voraxaze revenue figure.
- No major public Paragraph IV challenge, biosimilar launch or settlement has established near-term U.S. competitive entry.
- Manufacturing complexity, formulation stability and emergency distribution are important practical barriers.
- The product has defensible niche economics but limited potential for broad-market growth.
FAQs About Glucarpidase Market and Exclusivity
Is glucarpidase a biologic or a generic drug?
Glucarpidase is a recombinant biologic enzyme. A competing product would generally require a biosimilar-style development pathway rather than a conventional small-molecule ANDA.
How much does a dose of Voraxaze cost?
Historical U.S. reports placed the price near $10,000 per vial, with total treatment cost depending on patient weight, the number of vials used and institutional contracting. Actual net prices are not publicly disclosed.
Does glucarpidase have biosimilar competition?
No established U.S. biosimilar competitor has been publicly identified as commercially available. Development remains possible, but the small and irregular market reduces the financial incentive.
Why do hospitals stock an expensive drug used rarely?
Glucarpidase can rapidly reduce toxic methotrexate concentrations when delayed clearance creates a medical emergency. Hospitals treating high-dose methotrexate patients may stock it to avoid delays caused by emergency procurement.
What is the main future threat to Voraxaze revenue?
The primary risks are a competing recombinant enzyme, hospital efforts to reduce inventory costs, manufacturing disruption and the development of alternative methotrexate-clearance technologies. Conventional generic substitution is a lower-probability risk because glucarpidase is a biologic rescue enzyme.
References
- U.S. Food and Drug Administration. (2012). Voraxaze (glucarpidase) prescribing information.
- Boston Scientific Corporation. (2019). Boston Scientific completes acquisition of BTG plc.
- SERB Pharmaceuticals. (2020). SERB acquisition of BTG specialty pharmaceuticals business.
- Institute for Clinical and Economic Review. (2013). Final evidence report: Glucarpidase for methotrexate toxicity.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2021). Scientific considerations in demonstrating biosimilarity to a reference product.